Josu de la Fuente/imperial.nhs.uk
Apr 5, 2026, 17:42
Josu de la Fuente: Real World Data Shows Significant Risk of Subsequent HCT in SCD and Thalassemia
Josu de la Fuente, Consultant Paediatric Haematologist Director Blood and Marrow Transplant Programme at Imperial College Healthcare NHS Trust, shared a post on LinkedIn:
“Real-world data confirms a small but significant risk of the need for a subsequent HCT with no plateau over time in sickle and thalassaemia.
Real world data from HWP of EBMT presented today.”
Stay updated with Hemostasis Today.
-
Oct 8, 2026, 23:27Shayan Mohammadmoradi: Happy to Be Back at the Midwest Platelet Conference for Its 20th Meeting
-
Oct 8, 2026, 23:18Lorena Arranz: Honoured to Contribute to the 6th Global MPN Symposium
-
Oct 8, 2026, 23:06Denis Oduor: Serving Citizens and Saving Lives Through Blood Donation During National Customer Service Week 2026
-
Oct 8, 2026, 22:51Jan Hartmann: Speaking on Global Trends in Plasma Collection at the 50th Meeting of the Japanese Society of Blood Services
-
Oct 8, 2026, 22:49Akshat Jain: Proud to Announce the Publication of Advances in Sickle Cell Disease
-
Oct 8, 2026, 22:49Ed Shovelin: Extending the Platelet Aggregation Testing Window to 72 Hours
-
Oct 8, 2026, 22:48Abdulla A. Damluji: Anticancer Drugs and Thrombosis Mechanisms, Risk Factors, and Prevention
-
Oct 8, 2026, 22:46Miguel Escobar: My Research on Oral Health and Hemophilia
-
Oct 8, 2026, 22:44ISTH 2027 Abstract Submission Opens November 23